Clearside Biomedical (CLSD) Tops Q2 EPS by 3c

Clearside Biomedical (NASDAQ: CLSD) reported Q2 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $90 thousand versus the consensus estimate of $151.8 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce
• JPMorgan Upgrades Nanya Technology Corp (2408:TT) to Overweight